Key Takeaways
- No published human clinical trial has established a safe or effective KPV dose. All human protocols are researcher extrapolations from rodent data.
- KPV is a 339.4 g/mol tripeptide (Lys-Pro-Val) that acts on MC1R and MC3R receptors to suppress NF-kB and downstream cytokines including TNF-alpha and IL-6.
- The most-cited researcher dosing range is 0.5 mg to 1 mg subcutaneously once or twice daily, or 1 to 2 mg orally once daily for gut-targeted use.
- A standard 10 mg vial reconstituted in 2 mL bacteriostatic water yields 5 mg/mL; a 0.5 mg dose equals 0.1 mL on an insulin syringe.
- As a tripeptide, KPV has an expected short systemic half-life due to serum protease cleavage, which makes route of administration mechanistically important, not interchangeable.
What is KPV peptide dosage in plain terms?
Table of Contents
- What is KPV and how does it work mechanistically?
- Evidence ledger: what the research actually supports
- KPV dosage table: routes, amounts, and cycle length
- KPV 10mg vial: reconstitution math and label literacy
- What most KPV pages get wrong: bioavailability and route
- Stability, storage, and degradation chemistry
- Honest head-to-head: KPV vs. BPC-157 vs. approved IBD therapy
- What Reddit and community protocols report
- How to read a KPV certificate of analysis
- FAQ
- Sources
What is KPV and how does it work mechanistically?
KPV is the C-terminal tripeptide Lys-Pro-Val, a naturally occurring fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). The parent peptide alpha-MSH is a 13-amino acid neuropeptide produced by post-translational cleavage of pro-opiomelanocortin (POMC). KPV corresponds to positions 11-13 of alpha-MSH and retains measurable anti-inflammatory activity independent of the full peptide.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Receptor targets: KPV binds melanocortin receptors, primarily MC1R and MC3R. MC1R is expressed on immune cells including macrophages, monocytes, and dendritic cells, and also on gut epithelial cells, which is mechanistically relevant for oral delivery. MC3R is expressed centrally and in peripheral immune tissues.
Downstream signaling: Receptor binding inhibits NF-kB nuclear translocation and MAPK pathway activation. Both pathways are upstream drivers of pro-inflammatory cytokine transcription. In published cell culture and animal studies, this translates to reduced production of TNF-alpha, IL-6, and IL-1beta, and reduced neutrophil recruitment measured by myeloperoxidase (MPO) activity.
What the mechanism does NOT prove: Receptor binding in cell culture or reduced cytokines in mouse colitis models does not establish that the same signal cascade operates at the same magnitude in humans, at the doses achievable after human-route administration, with the peptide half-life seen in vivo. Mechanism is plausibility, not proof of clinical effect.
Evidence ledger: what the research actually supports
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| KPV reduces colon inflammation markers in mouse colitis models (oral or enema delivery) | Multiple animal studies (e.g., Brzoska et al.; Bhatt lab mouse colitis work) | Positive (reduced TNF-a, IL-6, MPO) | Moderate (animal) |
| KPV binds MC1R and MC3R to suppress NF-kB | In vitro receptor binding and cell signaling assays | Positive | Moderate (mechanism) |
| Oral KPV acts on gut epithelial MC1R locally before systemic absorption | Mechanistic/animal data; epithelial MC1R expression confirmed in human tissue | Plausible | Low (mechanism extrapolation) |
| KPV reduces skin inflammation in animal models | Animal studies (contact hypersensitivity models) | Positive | Low (animal) |
| KPV is safe and effective at any dose in humans | No human trial data | Unknown | Very low |
| Specific human dosing guidelines for KPV | None published | Not established | Very low |
KPV dosage table: routes, amounts, and cycle length
| Route | Reported dose range | Frequency | Typical cycle | Primary rationale |
|---|---|---|---|---|
| Subcutaneous injection | 0.5 mg to 1 mg | Once or twice daily | 4 to 8 weeks | Systemic anti-inflammatory, wound support |
| Oral (solution or capsule) | 1 mg to 2 mg | Once daily | 4 to 8 weeks | Gut mucosa targeting (IBD-type applications) |
| Topical (compounded cream) | No consensus; typically 0.1 to 0.5% w/w formulations discussed | Once or twice daily | Variable | Local skin inflammation |
| Enema (research setting) | Used in animal studies; human range not established | Daily in animal protocols | Short-term in studies | Direct colonic delivery (IBD research) |
Body weight scaling: Animal studies typically dose by mg/kg. Naive allometric scaling from mouse to human is unreliable across species due to differences in metabolic rate, body surface area, and protease activity. Do not apply direct mouse mg/kg doses to humans.
KPV 10mg vial: reconstitution math and label literacy
A 10 mg lyophilized KPV vial is the most common commercial unit. Here is the reconstitution math for common concentrations:
| Bacteriostatic water added | Resulting concentration | Volume for 0.5 mg dose | Volume for 1 mg dose |
|---|---|---|---|
| 1 mL | 10 mg/mL (10,000 mcg/mL) | 0.05 mL (5 units on U100 syringe) | 0.10 mL (10 units) |
| 2 mL | 5 mg/mL (5,000 mcg/mL) | 0.10 mL (10 units) | 0.20 mL (20 units) |
| 4 mL | 2.5 mg/mL (2,500 mcg/mL) | 0.20 mL (20 units) | 0.40 mL (40 units) |
Reconstitution technique: Inject bacteriostatic water slowly down the inside wall of the vial. Do not inject directly onto the lyophilized pellet and do not shake. Swirl gently until the pellet dissolves. The solution should be clear and colorless. Cloudiness, particulates, or color indicate contamination or degradation and the vial should be discarded.
Insulin syringe units: U100 insulin syringes mark in units where 100 units equals 1 mL. Units and microliters are numerically equal on a U100 syringe. 10 units equals 0.1 mL. This is where arithmetic errors most often occur, so verify your concentration before drawing up a dose.
What most KPV pages get wrong: bioavailability and route
This is the section that commodity pages omit entirely, and it changes the entire dosing calculus.
Oral bioavailability of peptides: KPV is a tripeptide. Small peptides up to three or four residues can sometimes survive gastric transit and absorb via intestinal peptide transporters, primarily PepT1 (SLC15A1), which is expressed on enterocytes. This is mechanistically different from larger peptides that are fully cleaved before absorption. There is published research (primarily Viennois et al., 2016 in the context of nanoparticle-delivered KPV) showing that oral KPV formulations can reach colon tissue in mouse models. However, this was studied in nanoparticle carrier form, not as a simple solution or capsule. Raw oral bioavailability of unformulated KPV solution is not well-quantified.
The implication most pages ignore: When a community protocol says "take 1 mg orally for gut issues," the assumption is that unformulated KPV in water or a capsule reaches colonic epithelium at therapeutically relevant concentrations. This may be partially true given tripeptide transporter activity, but the fraction that survives gastric acid and brush-border peptidases and reaches distal colon is unknown and likely variable. The nanoparticle delivery data should not be used to validate simple oral dosing.
Subcutaneous vs. oral is not interchangeable: Subcutaneous injection bypasses gut first-pass but then faces rapid systemic protease cleavage. The half-life of a tripeptide in serum is expected to be short, likely in the range of minutes. This means subcutaneous KPV may achieve a brief systemic anti-inflammatory pulse rather than sustained tissue exposure. Neither route has established human pharmacokinetics. Treating them as dose-equivalent is mechanistically unsound.
Stability, storage, and degradation chemistry
Why lyophilized powder is more stable: Peptide bond hydrolysis is a water-dependent reaction. In the dry lyophilized state, without free water to act as a reactant, degradation is orders of magnitude slower. Lyophilized KPV stored frozen (minus 20°C or colder) and protected from light can maintain integrity for a year or longer. This is a general property of lyophilized peptides, not a KPV-specific stability study finding.
Reconstituted solution degradation: Once water is added, several degradation pathways begin. Hydrolysis of the peptide bonds (particularly the Lys-Pro bond which is less susceptible to prolyl endopeptidase than the Pro-Val bond), oxidation of the lysine side chain amine, and microbial growth in non-bacteriostatic preparations. Bacteriostatic water contains 0.9% benzyl alcohol, which suppresses microbial contamination and extends usable life to approximately 30 days refrigerated (2 to 8°C). Plain sterile water lacks this protection and should be used within days.
Signs of degraded KPV solution: Cloudiness, visible particles, yellow or brown discoloration, or an unusual odor. A degraded peptide solution is not simply less potent. Degradation products are unknown compounds with unknown biological activity and should not be injected.
Freeze-thaw cycles: Each freeze-thaw cycle stresses peptide structure through ice crystal formation and concentration effects at the ice interface. Minimize freeze-thaw by aliquoting into single-use volumes before initial freezing.
Honest head-to-head: KPV vs. BPC-157 vs. approved IBD therapy
| Attribute | KPV | BPC-157 | Vedolizumab (approved IBD) |
|---|---|---|---|
| Human RCT data | None | None | Yes, multiple large Phase III trials |
| Mechanism clarity | High (MC1R/MC3R, NF-kB defined) | Moderate (multiple proposed pathways, less unified) | High (alpha4beta7 integrin blockade) |
| Animal evidence base | Moderate (colitis, skin models) | Broader (gastric, colonic, systemic models) | Pre-clinical plus full human trials |
| Oral delivery plausibility | Moderate (tripeptide PepT1 transport) | Moderate (stable gastric pentadecapeptide fragment) | IV or subcutaneous only |
| Known safety profile | Unknown | Unknown (human) | Well-characterized; infection risk, PML risk (rare) |
| Regulatory status | Research compound | Research compound | FDA-approved |
| Where KPV loses | KPV loses on evidence depth, safety data, and clinical validation against any approved therapy. It should not be considered an alternative to approved IBD treatment. | ||
What Reddit and community protocols report for KPV dosage
Search threads on r/Peptides and related forums (queried collectively as "kpv peptide dosage reddit") show consistent patterns in community self-experimentation:
- The most commonly cited subcutaneous dose is 0.5 to 1 mg once or twice daily, with some users reporting up to 2 mg per day.
- Oral dosing for gut-related complaints (described variously as colitis, Crohn's-like symptoms, leaky gut) is most often reported at 1 to 2 mg daily in solution or capsule form.
- Cycle lengths reported range from 4 to 12 weeks, with some users running longer open-ended protocols.
- Anecdotal tolerability appears reasonable in these reports, with few users reporting acute adverse events. However, these are self-selected, unblinded, uncontrolled reports with no systematic adverse event tracking.
- Absence of reported harm in community forums is not a safety signal. Rare or delayed adverse effects would not appear in self-reported short-term anecdotes.
Community data is hypothesis-generating at best. It identifies what doses people are using, not what doses are safe or effective.
How to read a KPV certificate of analysis
A legitimate supplier of research-grade KPV should provide a certificate of analysis (COA) from a third-party analytical laboratory. Here is what each section should contain:
| COA Section | What to look for | Red flag |
|---|---|---|
| Identity (MS) | Molecular weight confirmation matching 339.4 g/mol (free acid form) or the salt form labeled | No mass spec data; weight doesn't match |
| Purity (HPLC) | Greater than 98% purity by area | Below 95%; no HPLC trace provided |
| Sequence confirmation | Amino acid composition or sequencing confirming Lys-Pro-Val order | Absent; sequence listed without confirmation method |
| Endotoxin (for injectable) | LAL assay result below 1 EU/mg for research injectable use | No endotoxin test; test "on file but not provided" |
| Sterility | Sterility test for products marketed for injection | Absent for injectable-marketed products |
| Batch number traceability | COA batch number matches vial label | Generic COA not tied to your specific batch |
Salt form matters for dosing: KPV is often supplied as the acetate or TFA (trifluoroacetate) salt. The molecular weight of KPV acetate and KPV TFA salt differ from the free acid form. If your vial label says "KPV acetate" and you are dosing based on free acid calculations, you may be slightly off on molar dose. For the small doses used in research protocols this is unlikely to be clinically consequential, but it matters for precise experimental design.
FAQ
What is the typical KPV peptide dosage per day?
Human clinical dosing data does not exist. Researcher protocols extrapolated from rodent studies typically use 0.5 mg to 1 mg subcutaneously once or twice daily for systemic work, or 1 mg to 2 mg orally for gut-targeted applications. These figures are not FDA-validated.
How do I reconstitute a KPV 10mg vial?
Adding 2 mL of bacteriostatic water to a 10 mg vial yields 5 mg/mL (5000 mcg/mL). A 0.5 mg (500 mcg) dose then equals 0.1 mL on a 1 mL insulin syringe. Always confirm your vial label and use sterile technique.
Is oral KPV dosage different from injectable dosage?
Yes. Oral administration targets gut mucosa directly and bypasses the need for systemic absorption. Mouse studies using oral doses in the range of micrograms to low milligrams per kilogram reduced colitis markers. Subcutaneous dosing for systemic anti-inflammatory effect may require different titration and has different pharmacokinetic behavior.
What does a KPV dosage protocol look like?
Typical researcher protocols run 4 to 8 weeks. Common structures include daily subcutaneous injections of 0.5 to 1 mg, or oral capsule/solution dosing of 1 to 2 mg once daily. There is no peer-reviewed human trial to anchor these numbers.
What does KPV stand for and how does it work?
KPV is the C-terminal tripeptide Lys-Pro-Val, derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors MC1R and MC3R and inhibits NF-kB and MAPK signaling pathways to reduce pro-inflammatory cytokine production including TNF-alpha and IL-6.
Is KPV safe for human use?
No human safety or efficacy trials have been published. KPV is a research compound in most jurisdictions. Adverse effect profiles, drug interactions, and long-term safety data are unknown. Use outside formal research carries unquantified risk.
How stable is KPV in solution?
Reconstituted KPV in bacteriostatic water should be refrigerated at 2 to 8°C and used within approximately 30 days. Lyophilized powder is more stable and can be stored frozen for longer periods. Repeated freeze-thaw cycles degrade the peptide bonds. Discard any solution that is cloudy, colored, or particulate.
What does KPV do for gut inflammation specifically?
In mouse models of colitis, oral KPV reduced colon inflammatory markers including TNF-alpha, IL-6, and myeloperoxidase activity. The gut epithelium expresses MC1R, allowing luminal KPV to act locally before systemic absorption. This is mechanistically plausible but unconfirmed in humans.
How does KPV compare to BPC-157 for gut inflammation?
Both are research peptides with rodent-only gut inflammation data. BPC-157 has a broader published evidence base across more animal models. KPV has a more defined receptor mechanism via MC1R and MC3R. Neither has human RCT data. Neither should be considered equivalent to approved IBD therapies.
What should I look for on a KPV certificate of analysis?
Look for HPLC purity above 98%, confirmed molecular weight by mass spectrometry matching 339.4 g/mol for the free acid, endotoxin testing (LAL assay) for injectable products, and sterility testing. A generic COA not tied to your batch number is a sourcing red flag.
What is the half-life of KPV?
No published human pharmacokinetic data exists for KPV. As a tripeptide, it is susceptible to rapid enzymatic cleavage by serum proteases. Half-life in vivo is expected to be short, likely minutes to under an hour systemically. This is part of why local delivery routes are mechanistically explored.
What do Reddit and community forums say about KPV dosage?
Community posts commonly report 0.5 mg to 2 mg per day subcutaneously, or 1 to 2 mg orally for gut complaints. These are anecdotal, uncontrolled reports with no systematic safety tracking. They identify what people are using, not what is safe or effective.
Sources
- Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocr Rev. 2008;29(5):581-602. PMC indexed.
- Viennois E, Merlin D, Gewirtz AT, Chassaing B. "Dietary emulsifier-induced low-grade inflammation promotes colon carcinogenesis." Cancer Res. 2017 (context: same research group that published KPV nanoparticle colitis work, Viennois lab). See also: Viennois E et al. "Dietary Emulsifiers Directly Alter Human Microbiota Composition and Gene Expression Ex Vivo Potentiating Intestinal Inflammation." J Crohns Colitis. 2019.
- Viennois E, et al. "Self-assembly nanoparticles for colon-targeted delivery of the anti-inflammatory peptide KPV." Biomacromolecules. 2016;17(4):1283-1292.
- Luger TA, Brzoska T. "Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs." Ann Rheum Dis. 2007;66(Suppl 3):iii52-iii55.
- Catania A, Gatti S, Colombo G, Lipton JM. "Targeting melanocortin receptors as a novel strategy to control inflammation." Pharmacol Rev. 2004;56(1):1-29.
- Anand BS, Dey S, Mitra AK. "Current prodrug strategies via membrane transporters/receptors." Expert Opin Biol Ther. 2002;2(6):607-620. (PepT1 transporter review).
- Rao JN, Wang JY. "Regulation of Gastrointestinal Mucosal Growth." In: Colloquium Series on Integrated Systems Physiology. Morgan and Claypool Life Sciences. 2010. (Gut epithelial receptor expression context).
- FDA Orange Book: Vedolizumab (Entyvio) approved indication and labeling. FDA.gov. Accessed 2026.